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The important therapeutic approach for treating type 2 diabetes mellitus is to decrease the post-prandial glucose levels which could 
be done by decreasing the absorption of glucose through the inhibition of the carbohydrates-hydrolyzing enzymes such as α-amylase 
and α-glucosidase present in the small intestinal brush border that are responsible for the breakdown of oligosaccharides and 
disaccharides into monosaccharide’s and suitable for absorption. Inhibition of α-amylase generally considered as strategy for the 
treatment of disorders in carbohydrate uptake, such as diabetes and obesity. Among the marketed allopathic preparations 
carbohydrates-hydrolyzing enzymes Inhibitors like acarbose, voglibose etc delay carbohydrate digestion and prolong overall 
carbohydrate digestion time, causing a reduction in the rate of glucose absorption and consequently blunting the postprandial plasma 
glucose rise. Some of the plants are also considered as an important source of chemical constituent with potential for inhibition of α-
amylase and can be used as therapeutic purposes. In this review our efforts have been devoted to explore the mechanism based 
carbohydrates-hydrolyzing enzymes Inhibitors for the regulation of diabetes. 
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INTRODUCTION 
Enzymes are biological catalysts which are important in 
digestion and for other biological reactions. Luminal digestion 
is mainly due to enzymes secreted by salivary glands, stomach 
and pancreas. Chemical degradation of food also occurs by 
hydrolytic enzymes present in the brush border of small 
intestine termed as membrane digestion.[1,2,3] The source and 
sites of various luminal and membrane bound digestive 
enzymes are illustrated in Fig. 1[5] 
 
Fig. 1 Luminal and membrane bound digestive enzymes are 
illustrated 
METABOLISM OF CARBOHYDRATES 
Distribution of glucose after a meal 
[5,6,]
 
 
Fig. 2 Distribution of glucose after a meal 
 
Carbohydrate digestion 
Starch is composed of amylose, which is a linear alpha-1,4-
linked glucose polymer, and highly branched amylopectin 
consisting of linear alpha-1,4-linked glucose chains with alpha-
1,6-linked branch chains. Salivary and pancreatic alpha-
amylases catalyze the endo-hydrolysis of alpha-1,4-glucosidic 
linkages releasing mainly maltose, maltotriose and related 
alpha-1,6-oligomers. Further digestion takes place in the small 
intestinal brush border by alpha-glucosidases, which hydrolyze 
the terminal alpha-1,4-linked glucose residues as the final step 
in the digestion of dietary carbohydrates to release glucose. The 
alpha-glucosidase activities, first described as maltases, are 
associated with maltase-glucoamylase and sucrase-isomaltase. 
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In addition to alpha-1,4-glucosidic activity, sucrase-isomaltase 
displays specific activities against the alpha-1,2 linkages of 
sucrose and alpha-1,6 linkages of is maltose.[7,8] 
 
Digestion in Mouth 
Digestion of carbohydrates starts at the mouth, where they 
come in contact with saliva during mastication. Saliva contains 
a carbohydrate splitting enzyme called salivary amylase 
(ptyalin).[9,10] 
Action of ptyalin (salivary amylase) 
It is α - amylase, requires Cl- ion for activation and optimum 
pH 6-7. The enzyme hydrolyzes α-(1,4) glycosidic linkage at 
random, from molecules like starch, glycogen and dextrins, 
producing smaller molecules maltose, glucose and 
disaccharides maltotriose. Ptyalin action stops in stomach when 
pH falls to 3.0[10,11]  
α –Amylase 
Starch or glycogen            Glucose, Maltose, Maltotriose 
 
Digestion in Stomach 
No carbohydrate splitting enzymes are available in gastric 
juice. HCl may hydrolyze some dietary sucrose to equal 
amounts of glucose and fructose. 
 
Digestion in Duodenum 
Food reaches the duodenum from stomach where it meets the 
pancreatic juice. Pancreatic juice contains a carbohydrate-
splitting enzyme pancreatic amylase. 
Action of pancreatic Amylase 
It is also an α - amylase, optimum pH 7.1. Like ptyalin it also 
requires Cl- for activity. The enzyme hydrolyzes α-(1,4) 
glycosidic linkage situated well inside polysaccharide 
molecule. Other criteria and end products of action are similar 
of ptyalin.[10,11] 
 
Digestion in Small Intestine 
Action of Intestinal Juice 
Pancreatic amylase 
It hydrolyzes terminal α-(1-4), glycosidic linkage in 
polysaccharides and Oligosaccharide molecules liberating free 
glucose molecules. 
Lactase 
It is a β- glycosidase, its pH range is 5.4 to 6.0. Lactose is 
hydrolyzed to glucose and galactose. 
 
       lactase 
Lactose               Glucose + Galactose 
    
Maltase     
The enzyme hydrolyzes the α -(1,4) glycosidic linkage between 
glucose units in maltose molecule liberating two glucose 
molecules. Its pH range is 5.8 to 6.2. [11]  
        Maltase 
Maltose                 Glucose + Glucose 
 
Sucrase 
PH ranges 5.0 to 7.0. It hydrolyzes sucrose molecule to form 
glucose and fructose.[11] 
       Sucrase 
Sucrose                 Glucose + fructose 
 
INSULIN 
Insulin is a protein hormone secreted by β-cells of Islets of 
Langerhans of pancreas.[12] 
 
Chemistry 
 Insulin 51 amino acids in an insulin molecule. 
 They are two chain  Polypeptide . 
o Chain A-has-21 amino acids, 
o Chain B-had-30 amino acids. 
 Both chains are connected by Disulphide Bridge. 
 Half life of insulin - 4-6 minutes.[12,13,14] 
 
Fig. 3 Structure of Insulin 
C peptide=31-65, A chain=66-86, B chain=1-30 
 
Metabolic Role of Insulin 
Carbohydrate metabolism: Insulin produces lowering of blood 
glucose and increases glycogen stores. This is achieved at 
several metabolic stages.  
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 There is increased uptake of glucose, galactose by various 
tissues like muscles, adipose, mammary glands etc .It is 
due to increased translocation of glucose transporters from 
Golgi to plasma membrane. 
 Insulin induces the synthesis of glucokinase which 
phosphorylates and decreases the intracellular glucose in 
liver. 
 Insulin enhances glycolysis by inducing the synthesis of 
phosphofructokinse and pyruvate kinase. 
 Pyruvate dehydrogenase complex is activated via 
dephosphorylation of enzyme molecules which lead to 
increased production of acetyl- CoA from pyruvate. 
 
Fig. 4 Paradoxycal action of insulin 
 Insulin stimulates protein phosphatase-1 which 
dephosphorylates and activates key enzyme glycogen 
synthase. This leads to increased synthesis of glycogen. 
 Insulin reduces gluconeognesis by repressing at gene level, 
PEP (Phosphoenol pyruvate) carboxykinase, and it inhibits 
F-1, 6 bisphosphatase via F- 2, 6 bis phosphatase 
inhibition. 
 Insulin stimulates protein phosphatase-1 which 
dephosphorylates and activates key enzyme glycogen 
synthase. This leads to increased synthesis of glycogen. 
 Insulin reduces gluconeognesis by repressing at gene level, 
PEP carboxykinase, and it inhibits F-1, 6 bisphosphatase 
via F- 2, 6bis phosphatase inhibition. 
 Insulin decreases glycogenolysis by dephosphorylating 
glycogen phosphorylase (inactivate) and also repressing 
glucose - 6phosphatase. 
 It stimulates HMPshunt by inducing the enzymes glucose-
6 phosphate dehydrogenase, 6-phosphogluconate 
dehydrogenase. [13,14,15] 
Disorders of carbohydrate uptake may cause severe health 
problems such as diabetes and obesity[17]. Diabetes mellitus 
(DM) is a metabolic disorder resulting from deficiency in 
insulin secretion, insulin action, or both, promoting disturbance 
of carbohydrate, fat and protein metabolism[18]. Long term 
complications of diabetes mellitus include retinopathy, 
nephropathy, neuropathy, microangiopathy and increased risk 
of cardiovascular disease[19,20]. Therefore a therapeutic 
approach to treat diabetes is to decrease postprandial 
hyperglycemia. This can be achieved by the inhibition of 
carbohydrate hydrolyzing enzymes like alpha amylase and 
alpha glucosidase. Alpha glucosidase and alpha amylase are the 
important enzymes involved in the digestion of carbohydrates.  
 
Alpha amylase is involved in the breakdown of long chain 
carbohydrates and alpha glucosidase breaks down starch and 
disaccharides to glucose. They serve as the major digestive 
enzymes and help in intestinal absorption. Alpha amylase and 
alpha glucosidase inhibitors are the potential targets in the 
development of lead compounds for the treatment of 
diabetes.[16 ,22,23]  
 
The drugs commonly used in the treatment of diabetes such as, 
sulfonylureas, biguanide, glucosidase inhibitors, aldose 
reductase inhibitor, thiazolidinediones, carbamoylmethyl 
benzoic acid, insulin-like growth factor. They are used for 
treating type 2 diabetes mellitus is to decrease the post-prandial 
glucose evels [23,24]. This could be done by retarding the 
absorption of glucose through the inhibition of the 
carbohydrates-hydrolysing enzymes, alpha- glucosidase and 
alpha-amylase, present in the small intestinal brush border that 
are responsible for the breakdown of oligosaccharides and 
disaccharides into monosaccharide’s suitable for absorption. 
Inhibitors of these enzymes, like acarbose, delay carbohydrate 
digestion and prolong overall carbohydrate digestion time 
causing a reduction in the rate of glucose absorption and 
consequently blunting the postprandial plasma glucose rise [16, 
20,25]. 
 
IN-VITRO MODELS USED IN DIABETIC RESEARCH: 
Inhibition Of Carbohydrate Digesting Enzymes Are: 
 Alpha-amylase 
 Alpha-glucosidase 
 Sucrase 
 Maltase 
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ALPHA -AMYLASE ENZYME METHOD 
METHOD – A:[27,28]  
Mixture prepare containing 200ul of 0.02 M sodium phosphate 
buffer (Ph- 6.9), 20μl of enzyme  
    
 Test sample prepare with five different concentration (20-
100μg/ml)  
    
200ul of 1% (w/v) starch solution prepare 
    
Incubated for 10 min. at room temperature  
    
Addition 200μl of starch solution in all test tubes  
    
The reaction was terminated with the addition of 400μl -3, 5 
Dinitro salicylic acid (DNS) reagent  
    
Boling water bath for 5 min, cooled and diluted with 15 ml of 
distilled water 
    
Absorbance between control sample (without extract) and test 
sample measured at 540nm.  
 
The inhibition is calculated according to the formula 
Inhibition  % =
Abs 540 (control)-Abs 540 (drug sample) 
Abs 540 (control)
×100 
 
METHOD – B:[27] 
EXTRACTION OF WHEAT ALPHA AMYLASE 
500g of malted whole wheat flour was added slowly with 
stirring to 1 litre of 0.2% calcium acetate solution at room 
temperature and continuously stirred for 2 hours on a stirrer. 
The suspension was stored at 2°C to 3°C prior to heat 
treatment. Since beta-amylase interferes with the enzymatic 
determination of alpha-amylase it was inactivated by heating 
the extract at 70°C for 15 minutes. Alpha-amylase is resistant 
to inactivation by this treatment at pH between 6.5 and 8.0. the 
pH of the extract was first adjusted to 6.6 was cold 4% 
ammonium hydroxide. Heat treatment was carried out at 85°C 
to 90°C and other at 72°C to 74°C using a water bath with 
continuous stirring. The extract was then cooled to 2°C to 3°C 
until use. 
 
DETERMINATION OF WHEAT ALPHA-AMYLASE 
INHIBITOR ACTIVITY: 
200μl of 0.02 M sodium phosphate buffer, 20μl of enzyme and 
the plant extracts in concentration range 20-100μg/ml 
 
  Incubated for 10 minutes room temperature  
 
Addition of 200μl of starch in all test tubes 
 
  The reaction was terminated  
 
The addition of 400μl DNS reagent 
  
  Heated on boiling water bath for 5 min 
 
Cooled and diluted with 15 ml of distilled water 
 
  Absorbance was measured at 540 nm 
 
Inhibition  % =
Abs 540 (control)-Abs 540 (drug sample) 
Abs 540 (control)
×100 
 
The IC50 values were determined from plots of percent 
inhibition versus log inhibitor concentration and were 
calculated by linear regression analysis from the mean 
inhibitory values. Acarbose was used as the reference alpha-
amylase inhibitor. All tests were performed in triplicate. 
 
METHOD – C:[31,35]  
PORCINE PANCREATIC ALPHA-AMYLASE INHIBITION 
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Where Ac+ is absorbance of 100% enzyme activity (only 
solvent with enzyme), A c- is absorbance of 0% enzyme 
activity (only solvent without enzyme), As is absorbance of test 
sample (with enzyme), and Ab is absorbance of blank (a test 
sample without enzyme), respectively.   
 
ALPHA-GLUCOSIDASE ENZYME METHOD 
 
METHOD – A:[31] 
 
METHOD – B:[32,36] 
 
METHOD –C:[27] 
DETERMINATION OF YEAST ALPHA-GLUCOSIDASE 
INHIBITOR ACTIVITY:  
SUCRASE ENZYME METHOD
[34]
 
MALTASE ENZYME METHOD
[35]
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CONCLUSION 
The present review has provides information of various In-vitro 
studies used in antidiabetic assessment which can establish a 
mechanism for the antidiabetic activity of drug. In conclusion, 
more research is required for developing a potential and 
valuable anti diabetic therapies using alpha amylase alpha 
glucosidase inhibitors of plant origin and intensive studies of 
the mechanism of action of the known drug have provide 
further validation of several new molecular drug targets. 
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